亚盛医药耐立克销售收入同比激增93%,医保覆盖成关键驱动力

DoNews
Aug 22, 2025

亚盛医药近日公布2025年上半年业绩,其核心产品耐立克销售收入同比增长93%,达到人民币2.17亿元。业绩显著增长主要得益于该药物被纳入国家医保目录后覆盖范围的持续扩大,市场可及性进一步提升。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10